Member Info for one4one

Phase 1 is a half dose safety exercise......Phase 1b is a escalation to full dosage "Adults" phase 2 is when the Science talks Efficacy ?

Now do you mind im watching Emmerdale .... :-)))......🐭

As already mentioned earlier in my statement, we have raised further equity funds since the year end - firstly £2.5 million on 10 February 2026 and £3 million as recently as 28 April 2026. The purpose of these fundraises is to provide us with sufficient cash resources to finance in full the completion of the Phase I programme....." Hello the next phase is 1b the logistics of my mind informs me "placings......🐭

Lse please implement the laugh out loud button.....🐭

Lets work in harmony -----🐭

Helix has found Argon now they have to test the purity, Now we can play three card Brag :-))

Https://thatstocksguy.substack.com/p/small-caps-june-review

sidenote : from above link Great Western Mining saw CEO Ed Loye head to the States, and not for a picnic. I’ve also seen the videos from the site visit - the scheelite is lighting up like Christmas lights in Deck the Halls - I encourage you to watch the compilation which is easy to find. I’ll chat to Ed later this week for updates. I might even record our conversation.

Cash at 31 Dec 2025 was reported at about £1.59 million.....The company then raised an additional £5.5 million in early 2026.....Annual loss for 2025 was approximately £9.8 million .

@ £9.8m annual loss implements an average burn of roughly £800k per month....ball park figure of 8/9 months operational cash runway based on 2025 expenses/though as the trial travels it becomes more expensive.

AS there is no big pharma collaboration "Obliviously not until vlad produces clean efficacy data From phase 1B of which has stalled so i would counter-claim The recent BOD share awards/options are in anticipation of a longer development cycle before a collaboration of interest !

Based on the above further equity financing "Dilution" will be the source for future capital....🐭

GWMO up periscope 10.8 %......Hemogenyx Down 1.6 %....."C’est la vie"... :-))) ...🐭

Defibrillator on stand bye.....🐭

If the trial does not resume very soon then placings the BOD has taken 20% with no risk if HG-CT-1 is proven the BOD secure the reward...🐭

Its been a decade + since hemo diversified to car-t and the science has evolved from Autologous "Hemo " of which is slow costly non -scalable/accessibility & Timely of which Aml patients have not got During the times past the science has travelled from Autologous "in-vivo" to Allogenic "ex vivo" that is affordable of the shelf delivering Accessibility & now oral by -passing chemotherapy for the elderly and recent revelations of synthetic cells being manufactured from the Dna, over the years as the science has evolved i have up-dated the forum by highlighting the breakthroughs Via links as it saves typing for a week "LOL".....Cell therapy has been a interesting subject and the Question " which came first the chicken or the egg ? simple eggs for breakfast...Chicken for supper :-)))

Https://ecancer.org/en/news/28257-successfully-treated-aml-patients-may-hold-the-key-to-new-car-t-cell-therapy

Quick question if HG-CT-1 FL3 The dual antidote for Adults/paediatric ? B-cell acute lymphoblastic leukaemia (B-ALL) and paediatric leukaemia — which is quite different from leukaemia in adults, arising due to large genetic rearrangements and the fusion of oncogenes rather than the development of small “typos” in the genetic code as people age...🐭

DL1..."safety."....Dl.2 is where the science talks & until then the noise on this forum is nothing but Noise...🐭

I thank you kindly for all of your reply's & i will leave you to Argue amongst your selves, Because you know i am right :-))....🐭

Like a lion waiting at the oasis for a mug punter and Mattpr1 strolls bye....🐭

@JustHereForHemo you need to look at the bigger picture.

Autologous is a control ....Allogenic is the future....Analogous is the Holy Grail....🐭

@Haywain your reply is a rampers magic-eye in cryogenic storage as presently the rampers are losing their coolant of which is a sure sign of blowing the head gasket.....the science says maybe the market says eventually :-)))....🐭

@Jezza1977 you may look at the picture but i look into the picture....🐭

The rampers hype is over riding the speculation, lets take a reality check, Safety so far is encouraging if the higher dosage fails to produce clean efficacy data or toxicity shows then the trial stalls & the trial becomes more expensive requiring further equity though reversing the pols if the therapy works at higher dosage hemogenyx re-rates imho hemo are a small cap bio company and the enrolment of new patients is 1/2 @ a time until more patients have been enrolled at cohort 1b then it is to early to produce efficacy data,Lastly & sadly not all Aml patients that have been screened to join the clinical trial make it.....'C'est la Vie'.....🐭

The rampers have lost momentum, The clinical trial has travelled from cohort phase 1 Half dose with no amendments to the protocol and now on route to cohort phase 1B with the Adults escalating to full dosage of HG-CT-1.

The radio silence is normal between cohorts, as hemogenyx is a small cap bio company & with the the recent Equity raise ! "imho" Hemogenyx are operating patient 2 patient rarther than continuously enrolling, As mentioned in the Fluffy recent E O Y Results Hemogenyx state they have enough capital to concede phase 1"Hello" hemo are with credit now advancing to cohort phase 1B with the enrolment of the Adults escalating to full Dosage of HG-CT-1 so investors should align with further Equity Raises as the finance runway may slow the enrolment.

In CAR-T specifically, dose escalation is extremely cautious because toxicities can emerge late or become dose-dependent. Some companies pause between cohorts while waiting through DLT (dose-limiting toxicity) observation windows before moving to full dose, On a positive stance cohort phase 1

HG-CT-1 Half Dose safety window has enabled the clinical trial to travel to cohort phase 1B

The wording of a Rns/cryptic crossword....Read & reread....The scientifical future signals...MRD Resistance...Durability past 180days.....kinectics of marrow recovery.....the outcomes of Bridge---transplant.....cytokine (CRS) profiles at higher doses....evidence of CAR persistence and whether efficacy improves meaningfully at full dose....All of that thesis claims a credit then the big pharma will take notice.

Bottom line : Hemogenyx survived a FDA clinical hold and survived & For a company of this size, getting to active AML CAR-T dosing is not-trivial so in a nutshell it is not just the case of rolling up your sleeves & having a infusion.....Have a lovely b/holiday weekend....🐭